
臨床病態解析学講座

【研究プロジェクト名および概要】

I. がんの病態解析と新規診断・治療法の開発

1. 転移・再発におけるクローン選択とその分子基盤の解明
2. ゲノム不安定の獲得機構とその制御法の解析
3. Tumor cell dormancy の分子機構の解明
4. RNA 修飾を介した腫瘍発症・進展機構の解析

II. 非侵襲的心機能評価の研究

1. 超音波検査の新たな解析手法を用いた弁膜症評価に関する研究
2. 非侵襲的検査を用いた心筋虚血の検出に関する研究
3. 超音波検査を用いた心機能評価に関する研究

III. 臨床検査に根付いた研究開発

1. 凝固関連遺伝子の遺伝学的検査と、凝固因子活性値測定手法の開発

IV. 熊本県心血管エコー検査標準化プロジェクト

1. アンケート調査による熊本県の心血管エコー検査の現状評価
2. 臨床検査技師・医師間の技術レベル均てん化の試み

【教職員および大学院学生】	【メールアドレス】	【研究プロジェクト】
准教授 神力 悟	satorus@kumamoto-u.ac.jp	I, III, 研究総括
助教 宇宿 弘輝 (中央検査部)	h-usuku@kumamoto-u.ac.jp	II, IV
大学院生 Saruul Tungalag	(博士課程)	I
大学院生 Shiyang Deng	(博士課程)	I
技術補佐員 東 亜弥		

【連絡先】 電話/FAX: 096-373-5283 【ホームページ】 http://www2.kuh.kumamoto-u.ac.jp/Mol_Lab_Med/

【特殊技術・特殊装置】

1. アンプリコンシーケンス
2. mRNA シーケンス
3. ChIP シーケンス
4. RRBS (バイサルファイトシーケンス)
5. リアルタイム PCR
6. DNA シーケンサー
7. 経胸壁・経食道心エコー (2D, 3D)
8. 血管エコー
9. 運動負荷心電図
10. 24 時間 Holter ECG

【英文原著】

1. Tierens A, Kagotho E, [Shinriki S](#), Seto A, Smith A, Care M, Maze D, Sibai H, Yee K, Schuh A, Kim D, Gupta V, Minden MD, [Matsui H](#), Jose-Mario C. Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia. **Front Oncol.** 2023 (in press).
2. [Tungalag S](#), [Shinriki S](#), Hirayama M, Nagamachi A, Kanai A, Inaba T, [Matsui H](#). Ribosome profiling analysis reveals the roles of DDX41 in translational regulation. **Int J Hematol.** 2023 (in press).
3. Kanemaru A, [Shinriki S](#), Kai M, Tsurekawa K, Ozeki K, Uchino S, Suenaga N, Yonemaru K, Miyake S, Masuda T, Kariya R, Okada S, Takeshita H, Seki Y, Yano H, Komohara Y, Yoshida R, Nakayama H, Li JD, Saito H, Jono H. Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance. **Cancer Cell Int.** 2(1):358, 2022.
4. Misumi I, Yamakawa M, Harada M, Sato K, Tabira A, [Usuku H](#), Tsujita K. Severe hypotension during junctional rhythm in a patient with multiple cerebral infarcts. **J Cardiol Cases.** 27(2):84-87, 2022.
5. [Shinriki S](#), Hirayama M, Nagamachi A, Yokoyama A, Kawamura T, Kanai A, Kawai H, Iwakiri J, Liu R, Maeshiro M, [Tungalag S](#), Tasaki M, Ueda M, Tomizawa K, Kataoka N, Ideue T, Suzuki Y, Asai K, Tani T, Inaba T, [Matsui H](#). DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells. **Leukemia** 236(11): 2605-2620, 2022.
6. Sumi H, Hoshiyama T, Morihisa K, Noda K, Kaneko S, Kanazawa H, Ishii M, Fujisue K, Sueta D, Takashio S, [Usuku H](#), Matsushita K, Tsujita K. Effect of contact vector direction on achieving cavotricuspid isthmus block. **Sci Rep.** 13(1):2579, 2023.
7. [Shinriki S](#), [Matsui H](#). Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis. **Front. Oncol.** 12:992340, 2022.
8. Singh RS, Vidhyasagar V, Yang S, Arna AB, Yadav M, Aggarwal A, Aguilera AN, [Shinriki S](#), Bhanumathy KK, Pandey K, Xu A, Rapin N, Bosch M, DeCoteau J, Xiang J, Vizeacoumar FJ, Zhou Y, Misra V, [Matsui H](#), Ross SR, Wu Y. DDX41 is required for cGAS-STING activation against DNA virus infection. **Cell Rep.** 39(8):110856, 2022.
9. Kuriyama H, Kimura T, Mizuhashi S, Nishimura Y, Kanemaru H, IKajihara I, Makino K, Aoi J, [Matsui H](#), Fukushima S. A Japanese case of melanoma of unknown origin with a rare BRAFV600R mutation was successfully treated with BRAF/MEK inhibitors. **Drug Discov. Therapeut.** 16(5):256-257, 2022.
10. Ueda A, Nakajima M, Misumi Y, Nakahara K, [Shinriki S](#), Tasaki M, [Matsui H](#), Ueda M. Detection of Vascular Notch3 deposits in Unfixed Frozen Skin Biopsy Sample in CADASIL. **Front. Neurol.** 13: 881528, 2022.
11. Tabira A, Misumi I, Sato K, Matsuda H, Iwasaki T, [Usuku H](#), Tsujita K. Mid-ventricular Obstructive Cardiomyopathy after Takotsubo Cardiomyopathy: A Case Report. **Intern Med.** 2022 (in press).
12. Matsushita K, Kojima S, Hirakawa K, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Hanatani S, Sueta D, Kanazawa H, Takashio S, Arima Y, Araki S, [Usuku H](#), Suzuki S, Yamamoto E, Nakamura T, Soejima H, Kaikita K, Tsujita K. Differential effects of overweight/obesity depending on the severity of heart failure complicating acute myocardial infarction in Japan. **Prog Cardiovasc Dis.** S0033-0620(22)00141-4, 2022.
13. [Usuku H](#), Yamamoto E, Sueta D, Noguchi M, Fujisaki T, Egashira K, Morioka M, Komorita T, Oike F, Fujisue K, Hanatani S, Arima Y, Takashio S, Oda S, Kawano H, Matsushita K, Ueda M, [Matsui H](#), Tsujita K. Time-dependent change of relative apical longitudinal strain index in patients with wild-type transthyretin amyloid cardiomyopathy. **Int J Cardiol Heart Vasc.** 43:101146, 2022.
14. Morioka M, Takashio S, Nakashima N, Nishi M, Fujiyama A, Hirakawa K, Hanatani S, [Usuku H](#), Yamamoto E, Kidoh M, Oda S, Matsushita K, Ueda M, Tsujita K. Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild-Type Transthyretin Amyloid Cardiomyopathy. **J Am Heart Assoc.** 11(12):e024717, 2022.

15. Nishi M, Takashio S, Morioka M, Fujiyama A, Nakashima N, Hirakawa K, Hanatani S, Usuku H, Yamamoto E, Kidoh M, Oda S, Gushima R, Matsushita K, Fukushima S, Ueda M, Tsujita K. Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive ^{99m}Tc-Labeled Pyrophosphate Scintigraphy Findings. **Circ J**. 86(7):1113-1120, 2022.
16. Nagano M, Misumi I, Sato K, Haba K, Yamasaki H, Toyozumi Y, Usuku H, Tsujita K. Recurrent Syncope in a Case with Mediastinal Lymphoma. **Int Heart J**. 63(3):647-650, 2022.
17. Misumi I, Ogata A, Fukuda K, Sato K, Nagano M, Usuku H, Tsujita K. Constrictive pericarditis following mRNA COVID-19 vaccination in a patient with systemic sclerosis. **J Cardiol Cases**. 26(2):97-100, 2022.
18. Oike F, Usuku H, Yamamoto E, Marume K, Takashio S, Ishii M, Tabata N, Fujisue K, Yamanaga K, Sueta D, Hanatani S, Arima Y, Araki S, Oda S, Kawano H, Soejima H, Matsushita K, Ueda M, Fukui T, Tsujita K. Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. **ESC Heart Fail**. 9(3):1976-1986, 2022.
19. Egashira K, Sueta D, Kidoh M, Tomiguchi M, Oda S, Usuku H, Hidaka K, Goto-Yamaguchi L, Sueta A, Komorita T, Oike F, Fujisue K, Yamamoto E, Hanatani S, Takashio S, Araki S, Matsushita K, Yamamoto Y, Hirai T, Tsujita K. Cardiac computed tomography-derived myocardial tissue characterization after anthracycline treatment. **ESC Heart Fail**. 9(3):1792-1800, 2022.
20. Usuku H, Takashio S, Yamamoto E, Yamada T, Egashira K, Morioka M, Nishi M, Komorita T, Oike F, Tabata N, Ishii M, Yamanaga K, Fujisue K, Sueta D, Arima Y, Araki S, Oda S, Misumi Y, Kawano H, Matsushita K, Ueda M, Matsui H, Tsujita K. Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. **J Cardiol**. 80(1):56-63, 2022.
21. Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejima H, Matsushita K, Tsujita K. Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. **Nutr Metab Cardiovasc Dis**. 32(5):1227-1235, 2022.
22. Nakashima N, Takashio S, Morioka M, Nishi M, Yamada T, Hirakawa K, Ishii M, Tabata N, Yamanaga K, Fujisue K, Sueta D, Kanazawa H, Hoshiyama T, Hanatani S, Araki S, Usuku H, Yamamoto E, Ueda M, Matsushita K, Tsujita K. A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan. **ESC Heart Fail**. 9(3):1731-1739, 2022.
23. Sueta D, Yamamoto E, Usuku H, Suzuki S, Nakamura T, Matsui K, Akasaka T, Shiosakai K, Sugimoto K, Tsujita K; ESES-LVH Study Investigators. Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study - Protocol for a Multicenter, Open-Label, Exploratory Interventional Study. **Circ Rep**. 4(2):99-104, 2022.
24. Egashira K, Sueta D, Komorita T, Yamamoto E, Usuku H, Tokitsu T, Fujisue K, Nishihara T, Oike F, Takae M, Hanatani S, Takashio S, Ito M, Yamanaga K, Araki S, Soejima H, Kaikita K, Matsushita K, Tsujita K. HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. **Korean J Intern Med**. 37(1):96-108, 2022.
25. Fujisue K, Yamamoto E, Sueta D, Takae M, Nishihara T, Komorita T, Usuku H, Yamanaga K, Ito M, Hoshiyama T, Kanazawa H, Takashio S, Arima Y, Araki S, Soejima H, Kaikita K, Matsushita K, Tsujita K. Increased soluble programmed cell death-ligand 1 is associated with acute coronary syndrome. **Int J Cardiol**. 349:1-6, 2022.
26. Takashio S, Yamada T, Nishi M, Morioka M, Fujiyama A, Nakashima N, Hirakawa K, Hanatani S, Usuku H, Yamamoto E, Ueda M, Matsushita K, Tsujita K. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. **J Cardiol**. 79(1):50-57, 2022.

27. Fujisue K, Yamamoto E, Sueta D, Arima Y, Hirakawa K, Tabata N, Ishii M, Ito M, Yamanaga K, Hanatani S, Hoshiyama T, Kanazawa H, Takashio S, Araki S, Usuku H, Nakamura T, Soejima H, Kaikita K, Kawano H, Matsushita K, Tsujita K. A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers. **J Atheroscler Thromb.** 29(9):1285-1294, 2022.

【総説・解説】

1. 松井啓隆. 造血器腫瘍の責任遺伝子単離と機能解析. 日本臨床検査同学院通信 47 巻春季号 pp1-4, 2022.
2. 松井啓隆. 骨髄異形成症候群の遺伝子異常と疾患発症メカニズム. 日本検査血液学会雑誌 23 巻 1 号 pp173-182, 2022.
3. 松井啓隆. 血液検査領域における AI の導入. 検査と技術 50 巻 6 号 pp586-589, 2022.
4. 神力悟, 前城学, 松井啓隆. メカノセレクション がん転移過程における力覚応答性に基づくクローン選択. 臨床化学 51 巻 2 号 pp117-122, 2022.
5. 宇宿弘輝. 特殊な HFpEF. 月刊心エコー Journal of Clinical Echocardiography Vol 23 巻 12 号 pp1170-1179, 2022.
6. 塩津弘倫, 神力悟, 松井啓隆. 静脈血栓症における細胞外 miRNA の意義. 日本臨床検査医学会誌 70 巻 8 号 pp659-663, 2022.
7. 上岡 樹生, 永川 明香, 高橋 宏通, 松井 啓隆. 第 68 回学術集会 Reversed Clinico-pathological Conference 2(RCPC 2) ビリルビン増加を伴わない ALP、 γ GT 上昇を認めた症例(症例検討会). 日本臨床検査医学会誌 70 巻 3 号 pp231-235, 2022.

【著書】

1. 松井啓隆 (分担執筆). 骨髄穿刺法、生検法 (適応と方法). 今日の治療指針 第 8 版 医学書院 2022.